UniQure Stock Falls 37% After Huntington's Disease Trial Update

(RTTNews) - Shares of uniQure N.

(QURE) are falling about 37 percent on Tuesday morning after the company announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the treatment of Huntington's disease.